Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Current Deferred Revenue (2024 - 2025)

Gossamer Bio (GOSS) has 2 years of Current Deferred Revenue data on record, last reported at $24.0 million in Q3 2025.

  • For Q3 2025, Current Deferred Revenue fell 62.56% year-over-year to $24.0 million; the TTM value through Sep 2025 reached $24.0 million, down 62.56%, while the annual FY2024 figure was $17.0 million, N/A changed from the prior year.
  • Current Deferred Revenue reached $24.0 million in Q3 2025 per GOSS's latest filing, up from $23.5 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $66.7 million in Q2 2024 and bottomed at $17.0 million in Q4 2024.